Drug Profile
Clascoterone - Cosmo Pharmaceuticals
Alternative Names: Breezula; CB-03-01; Clascoterone - Cassiopea; Cortexolone 17alpha-propionate; WINLEVI; WinleviLatest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Cosmo Pharmaceuticals
- Developer Cassiopea; Cosmo Pharmaceuticals; Sun Pharmaceutical Industries
- Class Antiacnes; Esters; Pregnenediones; Propionates; Skin disorder therapies; Small molecules
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Acne vulgaris
- Phase III Alopecia
Most Recent Events
- 08 Mar 2024 Registered for Acne vulgaris (In adolescents, In adults) in Australia (Topical)
- 27 Sep 2023 Clascoterone licensed to Glenmark Pharmaceuticals Ltd. in Bulgaria, Czech Republic, Denmark, Finland, France, Hungary, Iceland, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain and Sweden, South Africa and United Kingdom
- 27 Sep 2023 Launched for Acne vulgaris (In adolescents, In children, In adults) in Canada (Topical)